BIOIO
- Biotech or pharma, therapeutic R&D
BIOIO is a therapeutics company developing first-in-class gerotherapies for aging-related diseases like T2DM. Its MOAT platform combines genome-wide screening, AI modeling, and in silico docking to uncover drug mechanisms and optimize compounds. Lead program BIOIO-1001 is a potent insulin sensitizer that activates the NMNAT-Sirt3 axis, improving mitochondrial health and reversing steatosis and heart failure markers in preclinical models. BIOIO-1001 has shown strong efficacy in both genetic and diet-induced models of diabetes and is expected to enter the clinic in H1 2027. BIOIO-2001 targets SPT for diabetic neuropathy and is based on CADs' inhibition of sphingolipid biosynthesis. BIOIO closed its seed round with top longevity investors and is preparing for Series A. Founded by Tim Peterson, PhD, and Joppe Nieuwenhuis, PhD, BIOIO is driven by functional genomics and translational science.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}